EVENITY ™ (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture

EVENITY Approved to Reduce the Risk of Fractures and Increase Bone Mineral Density in Men and Postmenopausal Women With Osteoporosis at High Risk of Fracture EVENITY in Japan is Being Co-Developed Through a Strategic Alliance With Amgen Astellas BioPharma THOUSAND OAKS, Calif. and BRUSSELS, Belgium, Jan. 8, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the Japanese Ministry of Health, Labor and Welfare has granted a marketing authorization for EVENITY™ (romosozumab) for the treatment of osteoporosis in patients at high risk of fracture.1 Amgen and UCB are co-developing EVENITY worldwide, with development in Japan being led by Amgen Aste...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news